Evaluation of RFID Localization System for Marking and Retrieving Breast Lesions
A Prospective, Single-Arm, Multicenter Clinical Study to Evaluate the Safety and Performance of the Health Beacons Radiofrequency Identification (RFID) Localization System for Marking and Retrieving Non-Palpable Breast Lesions
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Contacts and Locations
Study Locations
-
-
California
-
San Diego, California, United States, 92123
- Sharp Memorial Hospital
-
Torrance, California, United States, 90502
- Harbor-UCLA Medical Center
-
-
Colorado
-
Denver, Colorado, United States, 80218
- Exempla Healthcare
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Have had stereotactic or ultrasound-guided biopsy with marker placement
- Have a lesion or biopsy marker that is visible under ultrasound
- Have surgical target < 6 cm from the skin when lying supine
- Have a discreet surgical target
- Have a lesion in which the center/focal area is defined
- Be at least 18 years of age or older
Exclusion Criteria:
- Have a palpable lesion that does not require localization
- Require more than one localization needle for localization of the surgical target
- Have undergone previous open surgical biopsy or lumpectomy in the operative breast
- Have an implant in the operative breast
- Have a cardiac pacemaker or defibrillator device
Study Plan
How is the study designed?
Design Details
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Subjects scheduled to undergo lumpectomy
|
The radiologist or surgeon will place the Health Beacons RFID Tag under ultrasonic or stereotactic guidance.
The surgeon will use the Tagfinder to locate the lesion.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
The surgical target is visualized in the removed specimen AND the RFID Tag was removed from the patient's breast.
Time Frame: Within 96 hours after lumpectomy
|
The study endpoints are known soon after the lumpectomy procedure by 1) confirmation of the pathology lab examination; and 2) retrieval of the implanted RFID tag.
|
Within 96 hours after lumpectomy
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Study Director: Murray Reicher, MD, Health Beacons
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Anticipated)
Primary Completion
Study Completion (Anticipated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
Other Study ID Numbers
- S10-001
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.